The Effect of a Local Injection of a Platelet Concentrate on Infection and Healing of Surgical Wounds

August 11, 2016 updated by: Jens Rikardt Andersen

The Effect of L-PRP on Wound Healing and Wound Infection After Pancreaticoduodenectomy / Whipples Surgery

The purpose of this project is to investigate whether a combination of a local injection of platelet rich plasma (PRP) combined with a daily supplement of vitamin C, zinc, L-arginine, as well as high protein diet (1.5 g of protein per kilo body weight per day) can promote tissue healing in patients undergoing open upper-abdominal surgery.

Primary endpoint is cases of wound infection and secondary endpoints are time of tissue regeneration (days), judged by traditional clinical observation and experimentally assessed by ultrasound.

The experiment is performed as a parallel two-armed, randomized, controlled trial.

A total of 40 subjects will be included in the trial i order to ensure the power of the study, despite a drop off of up to 25%.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient at Rigshospitalets Surgical gastroenterology clinic
  • Planned to have a Pancreaticoduodenectomy preformed
  • Being able to understand Danish, the trial and what it means to be enrolled in the trial
  • Capable of signing a written consent
  • Living i the Regional Capital (excl. Bornholm) or the Regional of Sjælland (north of Næstved)

Exclusion Criteria:

  • Dysregulated diabetes mellitus type I or II
  • Alcohol consumption above 14 or 7 x 12 g alcohol per week (men vs women)
  • Participating in another clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Leucocyte - Platelet rich Plasma and Dietary Supplements

An application of an autologous platelet concentrate (20 ml). This is injected once, locally in the muscle after closure of the inner fascia and before closure of the outer fascia.

A daily dietary supplement of Vitamin C, Zinc and L-Arginine. Provided from POD2-3 until POD30

Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
Other Names:
  • L-PRP
A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
No Intervention: Treatment as usual
Patients are treated as usual.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients with wound infection assessed by traditional clinical observation of the cicatrice
Time Frame: From date of surgery until the date of first documented event of infection or date of death from any cause, whichever came first, assessed up to 30 days .

Infection are defined as a collection of pus in the wound that require revision.

It is assessed by observation from the hospital staff.

From date of surgery until the date of first documented event of infection or date of death from any cause, whichever came first, assessed up to 30 days .

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of days before the surgical wound are full epithelized assessed by observation of the cicatrice
Time Frame: Up to 30 days
Digital photos of the cicatrice will be collected and analyzed for the amount of remaining scab.
Up to 30 days
Other postoperative complications
Time Frame: Up to 30 days
Up to 30 days
Length of stay (LOS)
Time Frame: 30 days
30 days
Experience of pain assessed by a VAS (Visual analogue scale)
Time Frame: Up to 30 days
Up to 30 days
Mobilization assessed by "Timed Up & Go (TUG)"
Time Frame: Up to 30 days
Timed Up & Go, also known as TUG, measures the time it takes a study subject to stand up, walk 3 meters, turn around, walk back and sit down.
Up to 30 days
Inflammatory responds assessed by blood sample analysis of the acute phase reactant CRP (c-reactive protein)
Time Frame: Up to 30 days
Up to 30 days
Inflammatory responds assessed by blood sample analysis of the acute phase reactant leucucytes
Time Frame: Up to 30 days
Up to 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2016

Primary Completion (Anticipated)

February 1, 2017

Study Registration Dates

First Submitted

August 3, 2016

First Submitted That Met QC Criteria

August 11, 2016

First Posted (Estimate)

August 16, 2016

Study Record Updates

Last Update Posted (Estimate)

August 16, 2016

Last Update Submitted That Met QC Criteria

August 11, 2016

Last Verified

August 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wound Infection and Wound Healing

Clinical Trials on Leucocyte - Platelet rich Plasma

3
Subscribe